Intravitreal S100B Injection Leads to Progressive Glaucoma Like Damage in Retina and Optic Nerve

The glial protein S100B, which belongs to a calcium binding protein family, is up-regulated in neurological diseases, like multiple sclerosis or glaucoma. In previous studies, S100B immunization led to retinal ganglion cell (RGC) loss in an experimental autoimmune glaucoma (EAG) model. Now, the dire...

Full description

Bibliographic Details
Main Authors: Sandra Kuehn, Wilhelm Meißner, Pia Grotegut, Carsten Theiss, H. Burkhard Dick, Stephanie C. Joachim
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Cellular Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fncel.2018.00312/full
id doaj-6bc4ef28f0ed415e83c104ec3a420007
record_format Article
spelling doaj-6bc4ef28f0ed415e83c104ec3a4200072020-11-25T00:26:39ZengFrontiers Media S.A.Frontiers in Cellular Neuroscience1662-51022018-09-011210.3389/fncel.2018.00312410883Intravitreal S100B Injection Leads to Progressive Glaucoma Like Damage in Retina and Optic NerveSandra Kuehn0Wilhelm Meißner1Pia Grotegut2Carsten Theiss3H. Burkhard Dick4Stephanie C. Joachim5Experimental Eye Research Institute, University Eye Hospital, Ruhr-University Bochum, Bochum, GermanyExperimental Eye Research Institute, University Eye Hospital, Ruhr-University Bochum, Bochum, GermanyExperimental Eye Research Institute, University Eye Hospital, Ruhr-University Bochum, Bochum, GermanyDepartment of Cytology, Institute of Anatomy, Ruhr-University Bochum, Bochum, GermanyExperimental Eye Research Institute, University Eye Hospital, Ruhr-University Bochum, Bochum, GermanyExperimental Eye Research Institute, University Eye Hospital, Ruhr-University Bochum, Bochum, GermanyThe glial protein S100B, which belongs to a calcium binding protein family, is up-regulated in neurological diseases, like multiple sclerosis or glaucoma. In previous studies, S100B immunization led to retinal ganglion cell (RGC) loss in an experimental autoimmune glaucoma (EAG) model. Now, the direct degenerative impact of S100B on the retina and optic nerve was evaluated. Therefore, 2 μl of S100B was intravitreally injected in two concentrations (0.2 and 0.5 μg/μl). At day 3, 14 and 21, retinal neurons, such as RGCs, amacrine and bipolar cells, as well as apoptotic mechanisms were analyzed. Furthermore, neurofilaments, myelin fibers and axons of optic nerves were evaluated. In addition, retinal function and immunoglobulin G (IgG) level in the serum were measured. At day 3, RGCs were unaffected in the S100B groups, when compared to the PBS group. Later, at days 14 and 21, the RGC number as well as the β-III tubulin protein level was reduced in the S100B groups. Only at day 14, active apoptotic mechanisms were noted. The number of amacrine cells was first affected at day 21, while the bipolar cell amount remained comparable to the PBS group. Also, the optic nerve neurofilament structure was damaged from day 3 on. At day 14, numerous swollen axons were observed. The intraocular injection of S100B is a new model for a glaucoma like degeneration. Although the application site was the eye, the optic nerve degenerated first, already at day 3. From day 14 on, retinal damage and loss of function was noted. The RGCs in the middle part of the retina were first affected. At day 21, the damage expanded and RGCs had degenerated in all areas of the retina as well as amacrine cells. Furthermore, elevated IgG levels in the serum were measured at day 21, which could be a sign of a late and S100B independet immune response. In summary, S100B had a direct destroying impact on the axons of the optic nerve. The damage of the retinal cell bodies seems to be a consequence of this axon loss.https://www.frontiersin.org/article/10.3389/fncel.2018.00312/fullglaucomaanimal modelS100B proteinretinal ganglion cell damageoptic nerve degenerationelectroretinogram
collection DOAJ
language English
format Article
sources DOAJ
author Sandra Kuehn
Wilhelm Meißner
Pia Grotegut
Carsten Theiss
H. Burkhard Dick
Stephanie C. Joachim
spellingShingle Sandra Kuehn
Wilhelm Meißner
Pia Grotegut
Carsten Theiss
H. Burkhard Dick
Stephanie C. Joachim
Intravitreal S100B Injection Leads to Progressive Glaucoma Like Damage in Retina and Optic Nerve
Frontiers in Cellular Neuroscience
glaucoma
animal model
S100B protein
retinal ganglion cell damage
optic nerve degeneration
electroretinogram
author_facet Sandra Kuehn
Wilhelm Meißner
Pia Grotegut
Carsten Theiss
H. Burkhard Dick
Stephanie C. Joachim
author_sort Sandra Kuehn
title Intravitreal S100B Injection Leads to Progressive Glaucoma Like Damage in Retina and Optic Nerve
title_short Intravitreal S100B Injection Leads to Progressive Glaucoma Like Damage in Retina and Optic Nerve
title_full Intravitreal S100B Injection Leads to Progressive Glaucoma Like Damage in Retina and Optic Nerve
title_fullStr Intravitreal S100B Injection Leads to Progressive Glaucoma Like Damage in Retina and Optic Nerve
title_full_unstemmed Intravitreal S100B Injection Leads to Progressive Glaucoma Like Damage in Retina and Optic Nerve
title_sort intravitreal s100b injection leads to progressive glaucoma like damage in retina and optic nerve
publisher Frontiers Media S.A.
series Frontiers in Cellular Neuroscience
issn 1662-5102
publishDate 2018-09-01
description The glial protein S100B, which belongs to a calcium binding protein family, is up-regulated in neurological diseases, like multiple sclerosis or glaucoma. In previous studies, S100B immunization led to retinal ganglion cell (RGC) loss in an experimental autoimmune glaucoma (EAG) model. Now, the direct degenerative impact of S100B on the retina and optic nerve was evaluated. Therefore, 2 μl of S100B was intravitreally injected in two concentrations (0.2 and 0.5 μg/μl). At day 3, 14 and 21, retinal neurons, such as RGCs, amacrine and bipolar cells, as well as apoptotic mechanisms were analyzed. Furthermore, neurofilaments, myelin fibers and axons of optic nerves were evaluated. In addition, retinal function and immunoglobulin G (IgG) level in the serum were measured. At day 3, RGCs were unaffected in the S100B groups, when compared to the PBS group. Later, at days 14 and 21, the RGC number as well as the β-III tubulin protein level was reduced in the S100B groups. Only at day 14, active apoptotic mechanisms were noted. The number of amacrine cells was first affected at day 21, while the bipolar cell amount remained comparable to the PBS group. Also, the optic nerve neurofilament structure was damaged from day 3 on. At day 14, numerous swollen axons were observed. The intraocular injection of S100B is a new model for a glaucoma like degeneration. Although the application site was the eye, the optic nerve degenerated first, already at day 3. From day 14 on, retinal damage and loss of function was noted. The RGCs in the middle part of the retina were first affected. At day 21, the damage expanded and RGCs had degenerated in all areas of the retina as well as amacrine cells. Furthermore, elevated IgG levels in the serum were measured at day 21, which could be a sign of a late and S100B independet immune response. In summary, S100B had a direct destroying impact on the axons of the optic nerve. The damage of the retinal cell bodies seems to be a consequence of this axon loss.
topic glaucoma
animal model
S100B protein
retinal ganglion cell damage
optic nerve degeneration
electroretinogram
url https://www.frontiersin.org/article/10.3389/fncel.2018.00312/full
work_keys_str_mv AT sandrakuehn intravitreals100binjectionleadstoprogressiveglaucomalikedamageinretinaandopticnerve
AT wilhelmmeißner intravitreals100binjectionleadstoprogressiveglaucomalikedamageinretinaandopticnerve
AT piagrotegut intravitreals100binjectionleadstoprogressiveglaucomalikedamageinretinaandopticnerve
AT carstentheiss intravitreals100binjectionleadstoprogressiveglaucomalikedamageinretinaandopticnerve
AT hburkharddick intravitreals100binjectionleadstoprogressiveglaucomalikedamageinretinaandopticnerve
AT stephaniecjoachim intravitreals100binjectionleadstoprogressiveglaucomalikedamageinretinaandopticnerve
_version_ 1725343446326050816